EasyPeso Demonstrates Corporate Social Responsibility (CSR) in Fire Relief, Contributing to Bacoor City's Fire Rescue Efforts
MANILA, Philippines, Dec. 17, 2024 /PRNewswire/ -- EasyPeso, operated by Creditable Lending Corporation, is one of the leading fintech platforms in the Philippines that aims to bridge the financial services access gap for underserved groups. Beyond...
Molicel's Commitment to Aerospace-Grade Quality Recognized with AS9100
TAIPEI, Dec. 16, 2024 /PRNewswire/ -- Molicel, a global leader in ultra-high power cells, has achieved a significant milestone by securing the prestigious AS9100:D certification. This certification underscores Molicel's unwavering commitment to...
KOLON SPORT Athlete Yuan Jin Demonstrates Sportsmanship at Chiang Mai Thailand by UTMB®
CHIANG MAI, Thailand, Dec. 13, 2024 /PRNewswire/ -- Chiang Mai Thailand by UTMB®, the pinnacle event on the Asia-Pacific trail running calendar, concluded on 8 December 2024. As a key athlete representing KOLON SPORT, Yuan exemplified the brand's...
New Lunit Study Demonstrates Universal AI Model for Analysis of Immunohistochemistry Images
Research in npj Precision Oncology highlights multi-cohort training approach and accurate analysis of unseen immunohistochemistry data SEOUL, South Korea, Dec. 12, 2024 /PRNewswire/ -- Lunit (KRX:328130.KQ), a leading provider of AI-powered...
GOOD JOB Through Crash A Unique Perspective on Chery's Crash Test Lab
WUHU, China, Dec. 12, 2024 /PRNewswire/ -- Recently, Chery Auto released an unconventional and engaging video that takes viewers on an intriguing journey through its cutting-edge crash test lab. Through the unique perspective of a newly "hired"...
Live from ASH 2024 | Ascentage Pharma Releases Updated Data of Bcl-2 Inhibitor Lisaftoclax in MDS that Demonstrates Potential Clinical Benefits and Favorable Safety
ROCKVILLE, Md. and SUZHOU, China, Dec. 10, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in discovering, developing, and commercializing therapies to address global unmet medical needs primarily for...
Live from ASH 2024 | Ascentage Pharma's Bcl-2 Inhibitor Lisaftoclax in Combinations Demonstrates Potential Clinical Benefit in Patients with Prior Exposure to Venetoclax
ROCKVILLE, Md. and SUZHOU, China, Dec. 10, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in discovering, developing, and commercializing therapies to address global unmet medical needs primarily for...
Live from ASH 2024 | First Dataset of Olverembatinib in Combination with Bcl-2 Inhibitor Lisaftoclax Demonstrates Potential Clinical Benefits as a Chemotherapy-Free Regimen for Children with R/R Ph+ ALL
ROCKVILLE, Md. and SUZHOU, China, Dec. 10, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in discovering, developing, and commercializing therapies to address global unmet medical needs primarily for...
ATFX Demonstrates Consistent Strong Performance in Q3 2024 Finance Magnates Data
HONG KONG, Dec. 5, 2024 /PRNewswire/ -- ATFX, ranked 5th in the Finance Magnates Q3 2024 report, showcased impressive performance with total trading volumes reaching $733.4 billion on its MT4/MT5 platforms. This substantial figure highlights ATFX's...
CYP-006TK Demonstrates Safety and Efficacy in DFU Clinical Trial
MELBOURNE, Australia, Dec. 5, 2024 /PRNewswire/ -- Cynata Therapeutics Limited (ASX: "CYP", "Cynata", or the "Company"), a clinical-stage biotechnology company specialising in cell therapeutics, has successfully completed its Phase 1 clinical trial...